Clinical Trials Sponsored by Sienna Biopharmaceuticals

Total 2610 results

Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat

Subcutaneous Fat

Australia
Epirus Biopharmaceuticals (Switzerland) GmbH

Unknown

BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study

Rheumatoid Arthritis
Ethicon, Inc.
OMRIX Biopharmaceuticals

Completed

The Fibrin Patch Soft Tissue Study

Hemostasis

United States
Ethicon, Inc.
OMRIX Biopharmaceuticals

Completed

A Study to Evaluate the Safety and Effectiveness of EVICEL as an Adjunct to Sutured Dural Repair

Dura Defects

Belgium, Finland, France, Germany, Netherlands, United Kingdom
Nabi Biopharmaceuticals
Vanderbilt University

Completed

Evaluation of Consistency of StaphVAX Manufacturing Lots

Staphylococcal Infections

United States
Ethicon, Inc.
OMRIX Biopharmaceuticals

Completed

A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery

Cardiovascular, Neurologic (Spine), and General Surgery

United States
Sienna Labs

Completed

Long-term Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA

Acne Vulgaris

United States
Caliway Biopharmaceuticals Co., Ltd.

Recruiting

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

Subcutaneous Fat

United States
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Recruiting

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Solid Tumor | Classic Hodgkin Lymphoma

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Not yet recruiting

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

B-cell Non-Hodgkin's Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Not yet recruiting

IMM40H Phase I Dose Escalation and Expansion

Tumor
Sichuan Clover Biopharmaceuticals, Inc.

Recruiting

A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)

Chemotherapy-induced Thrombocytopenia (CIT)

China
Day One Biopharmaceuticals, Inc.

Recruiting

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Melanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditions

United States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
Tasly Biopharmaceuticals Co., Ltd.

Active, not recruiting

rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) (PROST-2)

Acute Ischemic Stroke

China
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

Moderate to Severe Ulcerative Colitis

United States, China, Pakistan, Ukraine
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

Moderate-to-severe Atopic Dermatitis

China
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

Moderate to Severe Persistent Asthma

United States, China, Hungary, Korea, Republic of, Poland
Caliway Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Subcutaneous Fat

United States
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

United States, Australia, China, New Zealand
Suzhou Connect Biopharmaceuticals, Ltd.

Withdrawn

CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

United States
Eiger BioPharmaceuticals
Ankara University

Completed

Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2) (LOWR-2)

Chronic Hepatitis D Infection

Turkey
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

Subcutaneous Fat

United States
Sichuan Clover Biopharmaceuticals, Inc.

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites

Malignant Ascites

China
Sichuan Clover Biopharmaceuticals, Inc.

Completed

A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion

Malignant Pleural Effusion

China
Kaiser Permanente
Keryx Biopharmaceuticals

Completed

Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients

Hyperphosphatemia

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

Subcutaneous Fat

Australia
Tasly Biopharmaceuticals Co., Ltd.

Completed

Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)

Acute Ischaemic Stroke

China
Tasly Biopharmaceuticals Co., Ltd.

Completed

Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial (PROUD)

Acute Ischaemic Stroke

China
Ethicon, Inc.
OMRIX Biopharmaceuticals

Completed

The Evicel Post-Authorization Surveillance Study

Hemorrhage | Peripheral Vascular Disease

United States
Ethicon, Inc.
OMRIX Biopharmaceuticals

Completed

The Fibrin Pad Liver Study

Hemorrhage

United Kingdom, Australia, New Zealand, Germany, Netherlands
Beijing Kanova Biopharmaceutical Co., LTD

Not yet recruiting

XKH001 Injection in Healthy Subjects

Asthma
Asklepios Biopharmaceutical, Inc.
Bayer

Not yet recruiting

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) (REGENERATE-PD)

Parkinson Disease
Hasten Biopharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study

Essential Hypertension

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection

Solid Tumor

United States
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of KM501 in Patients With Solid Tumors

Advanced Solid Tumors

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis

Gastrointestinal Diseases | Gastroesophageal Reflux | Esophageal Motility Disorders | Deglutition Disorders | Esophageal Diseases | Esophagitis | Reflux Esophagitis

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

Drug-drug Interaction Study of XZP-3621 Tablet

Healthy Subjects

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer

Advanced Bladder Carcinoma

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

ROS1 Rearrangement Non-small Cell Lung Cancer | ALK Rearrangement Non-small Cell Lung Cancer

China
Beijing Kanova Biopharmaceutical Co., LTD

Active, not recruiting

Phase I of XKH001Injection in Healthy Adults

Healthy Adults

China
Binhui Biopharmaceutical Co., Ltd.

Not yet recruiting

OH2 Administered by Intratumoral Injection

Solid Tumor
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZB-0004 in Patients With Solid Tumors

NSCLC | Advanced Solid Tumor

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of KM602 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS

AML | MDS

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients With Advanced Liver Cancer

Advanced Liver Cancer

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Clinical Trial of XZP-3287 for Material Balance

Healthy Male Subjects

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Non-small Cell Lung Cancer

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy Subjects

Healthy

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects

Nonalcoholic Steatohepatitis (NASH)

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Injection in Solid Tumors

Melanoma | Solid Tumor

China

Clinical Trials Sponsored by Sienna Biopharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations